상세 정보

underline
Metadata Downloads : dc(xml) or Excel
Cited 0 time in scopus ci

Title 

Targeted cytotoxic effect of anti-JL1 immunotoxin against a human leukemic cell line and its clinical implications

Authors 

Y K ShinY L ChoiE Y ChoiM K KimM C KookJ H ChungYang Kyu ChoiH S KimH G SongS H Park

Publisher 

Springer Verlag (Germany)

Issue Date 

2003

Citation 

Cancer Immunology, Immunotherapy, vol. 52, no. 8, pp. 506-512

Keywords 

geloninimmunotoxinJL1leukemiaantigenmonoclonal antibody jl 1unclassified drugbone marrow cellcancer cell culturecell proliferation

Abstract 

We have previously reported the identification of a unique thymocyte-specific surface molecule, JL1, which was detected using the monoclonal antibody (mAb), anti-JL1. Interestingly, JL1 was shown to be expressed in most leukemias, irrespective of their immunophenotype, and subpopulations of normal bone marrow (BM) mononuclear cells (MNCs). Here we investigated the potential usefulness of the anti-JL1 mAb as a therapeutic tool for leukemia. We demonstrated that the proliferation of cultured human leukemia cells was dramatically inhibited in vitro by anti-JL1 mAb conjugated with the polypeptide toxin, gelonin, but not by gelonin alone. We then systematically investigated the reactivity of the anti-JL1 mAb against normal human tissues to evaluate possible side effects along with various hematopoietic and nonhematopoietic tumor cell lines. All of 33 types of normal tissues except thymus and subpopulation of BM MNCs were clearly devoid of JL1 expression. Among tumor cell lines, all the nonhematopoietic cell lines tested were negative for JL1 expression, while some hematopoietic cell lines contained JL1 antigen. Collectively, the results showed the cytotoxic effects of anti-JL1-based immunotoxin against JL1-positive leukemic cells, sparing most normal tissues other than thymocytes and some BM MNCs. Therefore, we strongly suggest that gelonin-conjugated anti-JL1 mAb immunotoxin could be developed as a potential immunotherapeutic agent in the treatment of various types of JL1-positive acute leukemias.

Citation 

Cancer Immunology, Immunotherapy , 52(8): 506-512

ISSN 

0340-7004

Link 

http://dx.doi.org/10.1007/s00262-003-0374-y

Appears in Collections

1. Journal Articles > Journal Articles

Registered Date

2017-04-19


There are no files associated with this item.
qrcode

FusionCharts.
DSpace Software Coptright(c) 2010 MIT and Hewleft-Packard  /  KRIBB-REPOSITORY ( Email:jakim@kribb.re.kr)